Perspectives of healthcare professionals on training for quantitative G6PD testing during implementation of tafenoquine in Brazil (QualiTRuST Study)

PLoS Negl Trop Dis. 2024 Jun 5;18(6):e0012197. doi: 10.1371/journal.pntd.0012197. eCollection 2024 Jun.

Abstract

Effective radical cure of Plasmodium vivax malaria is essential for malaria elimination in Brazil. P. vivax radical cure requires administration of a schizonticide, such as chloroquine, plus an 8-aminoquinoline. However, 8-aminoquinolines cause hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, requiring prior screening to exclude those at risk. Brazil is pioneering the implementation of tafenoquine, a single-dose 8-aminoquinoline indicated for P. vivax patients with >70% of normal G6PD activity. Tafenoquine implementation in Manaus and Porto Velho, two municipalities located in the western Brazilian Amazon, included comprehensive training of healthcare professionals (HCPs) on point-of-care quantitative G6PD testing and a new treatment algorithm for P. vivax radical cure incorporating tafenoquine. Training was initially provided to higher-level facilities (phase one) and later adapted for primary care units (phase two). This study analyzed HCP experiences during training and implementation and identified barriers and facilitators. In-depth interviews and focus discussion groups were conducted 30 days after each training for a purposive random sample of 115 HCPs. Thematic analysis was employed using MAXQDA software, analyzing data through inductive and deductive coding. Analysis showed that following the initial training for higher-level facilities, some HCPs did not feel confident performing quantitative G6PD testing and prescribing the tafenoquine regimen. Modifications to the training in phase two resulted in an improvement in understanding the implementation process of the G6PD test and tafenoquine, as well as in the knowledge acquired by HCPs. Additionally, knowledge gaps were addressed through in situ training, peer communication via a messaging app, and educational materials. Training supported effective deployment of the new tools in Manaus and Porto Velho and increased awareness of the need for pharmacovigilance. A training approach for nationwide implementation of these tools was devised. Implementing quantitative G6PD testing and tafenoquine represents a significant shift in P. vivax malaria case management. Consistent engagement with HCPs is needed to overcome challenges in fully integrating these tools within the Brazilian health system.

MeSH terms

  • Adult
  • Aminoquinolines* / therapeutic use
  • Antimalarials* / therapeutic use
  • Brazil
  • Female
  • Glucosephosphate Dehydrogenase
  • Glucosephosphate Dehydrogenase Deficiency* / diagnosis
  • Health Personnel* / education
  • Humans
  • Malaria, Vivax* / drug therapy
  • Malaria, Vivax* / prevention & control
  • Male
  • Plasmodium vivax / drug effects

Substances

  • tafenoquine
  • Antimalarials
  • Aminoquinolines
  • Glucosephosphate Dehydrogenase

Grants and funding

This project was funded by National Council for Scientific and Technological Development (CNPq), Ministry of Health of Brazil, and Bill & Melinda Gates Foundation (Grant Number 442910/2019-3). This project was also funded by Medicines for Malaria Venture by grants from the Bill and Melinda Gates Foundation, Newcrest mining and the UK Government. This work was supported in whole or in part by the Bill & Melinda Gates Foundation (Global Health Grant Number OPP1059029), under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. ML and WM are supported by the Brazilian National Council for Scientific and Technological Development (CNPq). DB-S is supported by the Fundação de Apoio a Pesquisa do Estado do Amazonas (FAPEAM). Medicines for Malaria Venture and the Brazilian Ministry of Health were involved in the study design and conduct, the development of this publication and the decision to publish. Other donors had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.